Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.
All News
Inflammatory disorders are often accompanied by an increased mortality risk, either from secondary malignancy, infection or cardiovascular disease.
BE COMPLETE is published, showing that bimekizumab (BMK), a selective dual inhibitor of interleukin (IL)-17F and IL-17A, results in superior improvement in both skin and joint outcomes in psoriatic arthritis (PsA) patients who have previously failed treatment with a tumour necrosis factor-α (TNFα) inhibitor.
Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
